118 results on '"Gordon, C."'
Search Results
2. OP0237 DISTINCT IMMUNE NETWORKS STRATIFY ORGAN INVOLVEMENT AND RESPONSE TO B CELL TARGETED THERAPIES IN SYSTEMIC LUPUS ERYTHEMATOSUS
3. POS0106 BILAG-2004 LDA AND BST LDA ARE VALID TREAT TO TARGET IN SLE
4. OP0296 THE 2021 DORIS DEFINITION OF REMISSION IN SLE – FINAL RECOMMENDATIONS FROM AN INTERNATIONAL TASK FORCE
5. OP0289 LLDAS (LOW LUPUS DISEASE ACTIVITY STATE), LOW DISEASE ACTIVITY (LDA) AND REMISSION (ON- OR OFF-TREATMENT) PREVENT DAMAGE ACCRUAL IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) PATIENTS IN A MULTINATIONAL MULTICENTER COHORT
6. OP0129 BELIMUMAB AFTER RITUXIMAB SIGNIFICANTLY REDUCED IGG ANTI-DSDNA ANTIBODY LEVELS AND PROLONGED TIME TO SEVERE FLARE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
7. POS0705 BILAG-2004 INDEX ACTIVE DISEASE PREDICTS DEVELOPMENT OF DAMAGE
8. POS0748 EASY-BILAG: A NEW TOOL FOR FASTER AND MORE ACCURATE RECORDING OF BILAG-2004 DISEASE ACTIVITY IN SLE
9. POS0111 DEVELOPMENT OF DAMAGE AND MORTALITY IN AN INCEPTION COHORT OF SLE PATIENTS
10. OP0081 A CASE OF ATYPICAL MYCOBACTERIUM INFECTION COMPLICATING EXTRA-NODAL ROSAI-DORFMAN DISEASE IN A PATIENT WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
11. SAT0186 DEVELOPING PREDICTORS OF GLOBAL BILAG TREATMENT RESPONSE IN PATIENTS WITH LUPUS NEPHRITIS: MORE LESSONS FROM THE ASPREVA LUPUS MANAGEMENT STUDY GROUP (ALMS) DATA
12. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs
13. European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies
14. EULAR points to consider for conducting clinical trials in systemic lupus erythematosus: literature based evidence for the selection of endpoints
15. EULAR points to consider for conducting clinical trials in systemic lupus erythematosus
16. Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus
17. BILAG-2004 index captures systemic lupus erythematosus disease activity better than SLEDAI-2000
18. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics
19. The relationship between cancer and medication exposures in systemic lupus erythaematosus: a case–cohort study
20. Non-Hodgkin’s lymphoma in systemic lupus erythematosus
21. Prevalence and predictors of fragility fractures in systemic lupus erythematosus
22. EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis
23. Assessment of lupus: where are we now?
24. Antibodies to protein P in systemic lupus erythematosus
25. Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial)
26. AB0603 Periodontal Disease is Common in Patients with Systemic Lupus Erythemathosus
27. OP0044 Effects of Atacicept on Disease Activity in Patients with Moderate to Severe Systemic Lupus Erythematosus: APRIL-SLE Randomized Trial: Table 1.
28. THU0013 Longterm Outcomes of Children Born to Mothers with SLE Exposed to Azathioprine in Pregnancy
29. THU0023 Correlation of Laboratory and Clinical Parameters with British Isles Lupus Assessment Group Response in an Open-Label Extension Study of Epratuzumab in Systemic Lupus Erythematosus
30. THU0430 A Survey on Patient and Physician Perspectives on Family Planning and Pregnancy Issues – Does Condition Matter?
31. OP0120 A Systematic Analysis of the Safety of Prescribing Anti-Rheumatic Immunosuppressive and Biologic Drugs in Pregnant Women with Inflammatory Arthritis: Table 1
32. FRI0093 A Systematic Analysis of the Safety of Prescribing of Anti-Rheumatic, Immunosuppressive and Biologic Drugs in Men Trying to Conceive
33. FRI0292 Children born to mothers with sle: no increase in males and hydroxychloroquine does not protect against neonatal lupus
34. AB0696 Measurement of arterial stiffness in a cross-section of SLE patients and relationship to treatment with intravenous methlyprednisolone – a pilot study
35. SAT0236 Role of serological markers at baseline and follow-up in predicting biopsy proven lupus nephritis
36. THU0272 Epratuzumab Maintains Improvements in Disease Activity for Over 2 Years in Patients with Moderate-to-Severe Systemic Lupus Erythematosus: Results from an Open-Label Long-Term Extension Study (Sl0008)
37. FRI0291 Long term outcomes of children born to mothers with sle: predictors of child development and infections
38. AB0617 Characterization of SLE patients experiencing flares in epratuzumab clinical trials
39. SP0029 Adult neuropsychiatric lupus
40. OP0064 Joint EULAR/ERA-EDTA recommendations for the management of adult and pediatric lupus nephritis
41. THU0277 Epratuzumab: Sustained Safety Profile and Effect on Corticosteroid Use on Long-Term Treatment in Patients with Moderate-to-Severe Systemic Lupus Erythematosus: Results from an Open-Label Long-Term Extension Study (Sl0008)
42. OP0119 Pharmacodynamic Effects of Atacicept in SLE Patients: 52-Week Data from the April-SLE Trial
43. THU0276 Efficacy and Safety of Atacicept for Prevention of Flares in Patients with Moderate to Severe Systemic Lupus Erythematosus (SLE): 52-wk Data (April-SLE Trial)
44. THU0286 Immunologic Response to Long-Term Epratuzumab Treatment in Sl0008, An Open-Label Long-Term Extension Study in Patients with Moderate-to-Severe Systemic Lupus Erythematosus
45. Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus
46. An assessment of disease flare in patients with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of SELENA
47. European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies
48. Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus
49. EULAR points to consider for conducting clinical trials in systemic lupus erythematosus: literature based evidence for the selection of endpoints: Table 1
50. EULAR points to consider for conducting clinical trials in systemic lupus erythematosus
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.